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Responder analysis is in common use in clinical trials, and has been described and endorsed in regulatory
guidance documents, especially in trials where “soft” clinical endpoints such as rating scales are used.
The procedure is useful, because responder rates can be understood more intuitively than a difference in
means of rating scales. However, two major issues arise: 1) such dichotomized outcomes are inefﬁcient
in terms of using the information available and can seriously reduce the power of the study; and 2) the
results of clinical trials depend considerably on the response cutoff chosen, yet in many disease areas
there is no consensus as to what is the most appropriate cutoff. This article addresses these two issues,
offering a novel approach for responder analysis that could both improve the power of responder
analysis and explore different responder cutoffs if an agreed-upon common cutoff is not present. Spe-
ciﬁcally, we propose a statistically rigorous clinical trial design that pre-speciﬁes multiple tests of
responder rates between treatment groups based on a range of pre-speciﬁed responder cutoffs, and uses
the minimum of the p-values for formal inference. The critical value for hypothesis testing comes from
permutation distributions. Simulation studies are carried out to examine the ﬁnite sample performance
of the proposed method. We demonstrate that the new method substantially improves the power of
responder analysis, and in certain cases, yields power that is approaching the analysis using the original
continuous (or ordinal) measure.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In many disease areas inwhich “hard” clinical endpoints such as
mortality are not appropriate measures of efﬁcacy, rating scales and
other continuous measures are used for the evaluation of treat-
ments. For instance, in schizophrenia clinical trials, the MATRICS
Consensus Cognitive Battery (MCCB) or the Negative Symptom
Assessment-16 (NSA-16) are frequently used instruments for
evaluating psychopathology in study subjects. Other examples
include the use of the Expanded Disability Status Scale (EDSS) in
multiple sclerosis trials, the use of exercise tolerance (ET) measures
in trials of heart failure therapies, and etc. In such studies, overall
treatment effect has typically been tested by assessing the differ-
ence in mean change over time of the continuous (or ordinal)
measure between the treatment and control group. Although such
analyses are usually the primary outcomes, one problem is that the
translation of the results into clinical practice is difﬁcult. We might
not know what, for example, a difference which is statistically
signiﬁcant but amounts to only 1 MCCB point in magnitude meansnc. This is an open access article ufrom a clinical perspective. Such a problem can be addressed by
using a responder analysis, in which each subject is classiﬁed as
either a “responder” or a “non-responder”, and the proportions of
patients who beneﬁt are quantiﬁed and compared between treat-
ment groups. A common approach is to deﬁne a threshold for the
change from baseline in the continuous (or ordinal) endpoint, and
deﬁne a patient as a “responder” if his/her change value is above (or
below) the threshold.
Responder analysis provides several beneﬁts and hence is in
many cases proposed or recommended by regulatory guidance or
clinical communities to be used in clinical trials. For example, draft
guidance from the FDA on patient-reported outcomes speciﬁcally
endorsed the responder analysis as an alternative approach to
assessing clinical relevance [1]. The procedure is useful, because
responder rates can be understood more intuitively than a differ-
ence in means of rating scales. It also helps ensure that a reported
statistically signiﬁcant result represents a clinically meaningful
beneﬁt. However, two major issues arise from this procedure. First,
it is well known that dichotomization tends to result in a loss of
statistical power compared to an analysis of the original continuous
variable. The procedure hence is inefﬁcient in terms of using the
information available and requires greater sample size in clinicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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issue with responder analysis is that the results of clinical trials
depend considerably on the response cutoff chosen. Yet in many
disease areas across different clinical trials, various deﬁnitions of
response have been used, and there is no consensus as to which is
the most appropriate one [3]. If a cutoff is chosen post hoc, this is
potentially an inappropriate manipulation of the data.
The issues and challenges inherent in the responder approach
deserve particular attention in the development and licensing of
new therapeutics. The present paper addresses the two issues
mentioned above, offering a novel approach for responder analysis
that could both improve the efﬁciency and power of responder
analysis and explore different responder cutoffs if an agreed-upon
common cutoff is not present.
Pre-speciﬁcation of the responder cutoff and a properly planned
statistical analysis are essential to avoid multiple comparisons and
inﬂated type I error rates. But how canwe pre-specify whenwe are
not certain which responder cutoff is the optimal one? Ganju et al.
recently proposed to analyze clinical trial data by pre-specifying
multiple test statistics and using a combined statistic e the mini-
mum p-value e for inference when there is uncertainty about what
candidate primary endpoint, hypothesis, or statistical test to use in
planning a clinical trial [4e7]. The critical value for hypothesis
testing comes from permutation which consists of re-randomizing
the treatment assignments and calculating the combined statistic.
For instance, for a trial with a time-to-event endpoint, it might be
unclear at the planning stage of the trial whether a log-rank test or
a stratiﬁed log-rank test would be more appropriate for the anal-
ysis. Using the proposed method, the trialists can pre-specify both
tests and use the minimum of the p-values as the new test statistic.
It has been shown that the method, referred to as MinP, is robust,
controls the type I error rate, and provide statistical power that is
closest to the best-performing statistic.
In this paper, we borrow the idea from Ganju et al. and extend
the use of MinP to clinical trials analyzed by the responder
approach. We propose a statistically rigorous clinical trial design
that pre-speciﬁes multiple tests of responder rates between treat-
ment groups based on a range of pre-speciﬁed responder cutoffs,
and uses the minimum of the p-values for formal inference. The
null hypothesis associated with the multiple tests is that there is no
treatment effect however the “responder” is deﬁned. The alterna-
tive hypothesis is that there is a signiﬁcantly greater proportion of
responders in the new treatment group, with the criterion for
“responding” being one of the pre-speciﬁed cutoffs. The proposed
method therefore provides not only a formal test for the treatment
effect, but also an estimate of the optimal responder cutoff, which
could be carried forward into future trials. More importantly, we
show that the proposed method, which we will refer to as MinP
responder analysis in the rest of this paper, substantially improves
the power of responder analysis. Inmany cases, theMinP responder
analysis yields power that is approaching the analysis using the
original continuous (or ordinal) measure.
The rest of the paper is structured as follows. In Section 2, we
describe the proposed method. The method is then illustrated on a
real data example in Section 3, and simulation studies evaluating
the performance of the MinP responder analysis are presented in
Section 4. Discussions and conclusion are given in Section 5.
2. Method
2.1. Design considerations
In general, suppose that the clinical endpoint is a continuous
variable, Y, such that larger values represent better efﬁcacy. Note
that Y could represent a measurement taken at the conclusion ofthe trial or a change in that measurement from its baseline value.
Assume, without loss of generality, a two-treatment trial with NA
subjects randomized to treatment A (e.g. experimental treatment)
and NB to treatment B (e.g. control). There is interest in the mean
difference in this endpoint, m, between the experimental treatment
and the control.
The difference in treatment effects can be determined using the
original continuous scale. In this case, the typical null hypothesis
(assuming one-sided testing) is that of no difference, or m  0,
versus the alternative hypothesis m > 0.
Alternatively, with responder analysis, a threshold value is
deﬁned above which a subject is considered to be a “responder”,
and belowwhich a subject is considered to be a “non-responder”. If
we let y0 represent the threshold value, then
W ¼

1 if Y  y0
0 if Y < y0
is a binary variable indicating whether or not the subject is a
responder. Now let pA and pB be the response rates in the experi-
mental group and the control group, respectively. Therefore the
null hypothesis for the responder analysis is pA  pB, and the
alternative is pA > pB. If the responder null hypothesis is rejected
then both statistical signiﬁcance and clinical relevance are
concluded. When the responder cutoff value y0 is not well estab-
lished and properly validated before the study, however, the results
from such responder analysis could be inadequate or irrelevant.
Moreover, as pointed out before, this approach substantially reduce
the power of the study as information is lost through dichotomi-
zation the continuous endpoint.2.2. MinP responder analysis procedure
Consider a setting for which there is a lack of consensus on the
proper responder cutoff to use. Without loss of generality, assume
that the continuous endpoint (and hence the responder cutoff y0)
take values in the interval (0, 100). The objective of the proposed
design is to
1. Formally test for any treatment effect, i.e. determining whether
a signiﬁcantly greater proportion of subjects in the experimental
arm “respond” to the treatment compared to the control arm
based on a certain responder cutoff; and
2. Identify optimal responder cutoff which could be carried for-
ward into future trials.
As the responder cutoff point is not well-established, we design
the trial by pre-specifying multiple tests of responder rates be-
tween treatment groups based on a range of pre-speciﬁed
responder cutoffs. Based on prior medical knowledge and discus-
sion with the clinical team, a series of plausible candidate
responder cutoffs {y0,k: k ¼ 1, 2,…, K} in the interval (0, 100) can be
pre-speciﬁed. For instance, {y0,k} ¼ {10, 20, 30, …, 90}. For each
candidate cutoff y0,k, a proportion test Tk will be performed to test
the null hypothesis that pA  pB, resulting in a series of p-values
{pk}. A natural approach to converting a series of p-values that are
calculated over the range of possible cutoff values into a single
statistic is then to take the minimum:
minP ¼ minðp1; …; pKÞ
Because of the well-known multiple testing problem, the stan-
dard asymptotic theory does not apply to the new statistic,minP. To
provide a statistically valid p-value forminP, we propose to use the
permutation distribution of minP, in which the treatment group
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Ganju et al. is summarized below [4]:
i. From the K pre-speciﬁed proportion tests ﬁt to the data,
obtain minPobs ¼ minðp1; …; pKÞ;
ii. Re-randomize treatments A or B to the NA þ NB subjects
maintaining the same NA/NB ratio as that observed. This can
be more easily understood by envisioning the data as an
(NA þ NB) by 2 matrix, where one column is the response y
and the other column contains the actual treatment assign-
ments. Permutation or re-randomization is achieved by
randomly re-ordering the labels ‘A’ or ‘B’ of the treatment
vector. If the trial design is stratiﬁed such that randomization
occurred within stratiﬁcation levels, then permutations
should be carried out within strata to reﬂect the design.
iii. Repeat step ii L times, and denote the minimum p-value for
the lth permutation minP*l (l ¼ 1, 2, …, L). A large enough
subset of all possible permutations, rather than the complete
set, which is often infeasible to generate, sufﬁces. The smaller
the a, the larger the number of permutations might be
needed for more accurate estimation. The distribution of
minP* denotes the permutation null distribution.
iv. The p-value of minPobs is 1L
PL
l¼1IðminP*l < minPobsÞ, where I()
denotes the indicator function that takes the value 1 if the
condition in parentheses is true and 0 otherwise.
v. The null hypothesis is rejected at level a if the p-value of
minPobs < a.
If the permutation procedure rejects the null hypothesis of no
treatment effect, the next step is to identify the responder cutoff
above which a subject will be considered a “responder”. Naturally
the responder cutoff that produces the minimum p-value can be
selected as the optimal cutoff point to be carried forward to future
trials. In some cases, a few neighboring cutoff points might produce
similarly small p-values. In this case, we recommend that other
practical considerations, such as clinical interpretation, sample size
of the potential “responder” group, etc., should be taken into ac-
count when selecting the responder cutoff for future studies.
3. Simulation studies
In this section, we evaluate the performance of MinP procedure
for responder analysis in the context of trials with two treatment
groups, active and control. The clinical endpoint of the trial is
assumed to be continuous. Different analysis strategies are consid-
ered, including 1) comparison of the means of the two groups; 2)
responder analysis, i.e. comparison of responder rates with a pre-
speciﬁed responder cutoff; and 3) the MinP procedure for
responder analysis. Two main scenarios are considered, and in each
scenariowe investigate the behaviorof the type I errorand thepower
undereach analysis strategy. Forboth simulation studiesweconsider
clinical trialswith a sample size of 200 per group,which represents a
typical Phase II clinical trial. The treatment difference is considered
signiﬁcant at the 0.05 level if the p-value is less than 0.05.
In Scenario 1, consider the measurement, Y, being a normally
distributed variable with a known variance. Without loss of gen-
erality, assume a truemean value in the control group of -m/2, a true
mean value in the experimental group of m/2, and an equal standard
deviation of 24 such that most of the observations fall within [-100,
100]. Suppose a measurement value greater than 0 indicates
improvement. For the MinP procedure, we use a grid of candidate
responder cutoff values of 10, 20, 30,…, 90, i.e. {y0,k} ¼ {10, 20, 30,
…, 90}. In real clinical trial scenarios, a narrower range of candidate
cutoff values might be used given prior medical knowledge and
clinical input.We performed simulations with m ¼ 0, 2, 3, and 4. Table 1 shows
the type I error and the power of detecting a treatment effect with
different analysis strategies. As expected, the type I error is
controlled under all analysis strategies. Under the alternatives,
testing the difference in means (a t-test in this case) always gives a
greater power compared to a responder analysis, which is not
surprising as the t-test utilizes more information than the propor-
tion test. Compared to the single proportion tests, the MinP pro-
cedure improves the power of detecting a treatment effect
substantially, by around 4%, 7%, and 5% respectively, under each
conﬁguration. In other words, MinP is a combination of all single
responder tests speciﬁed, yet its power is greater than the best of
these single tests. This would translate to a much smaller sample
size needed if the responder analysis is the desirable analysis
method for the trial.
Scenario 2 assumes the measurement Y follows a beta distri-
bution with shape parameters a and b. Without loss of generality,
assume true a ¼ 2 for both treatment groups, a true b parameter in
the control group of bA, and a true b parameter in the experimental
group of bB. All observations fall within [0,1] and a grid of candidate
responder cutoff values of 0.1, 0.2, 0.3, …, 0.9, i.e. {y0,k} ¼ {0.1, 0.2,
0.3,…, 0.9}, is pre-speciﬁed for theMinP procedure. The type I error
and power results under 4 conﬁgurations are presented in Table 2.
Again, the type I error is controlled under all analysis strategies.
Under the alternatives, we observe the power may suffer dramat-
ically if an inappropriate responder cutoff is chosen. For instance,
under conﬁgurations 3 (bA¼ 2.4) and 4 (bA ¼ 2.6), the lost in power
can be 25% ormore if a cutoff value of less than 0.4 (including 0.4) is
chosen. Overall, compared to the single proportion tests, the MinP
procedure improves the power of detecting a treatment effect by
2%e18% under conﬁguration (2), 8%e51% under conﬁguration (3),
and 7%e74% under conﬁguration (4). The optimal power is again
achieved by testing the mean difference of the continuous variable,
but the advantage over MinP is minimum (5%e6% in all alternative
conﬁgurations).
4. Example
Finally we illustrate the performance of the proposed MinP
method using data from published clinical trials of heart failure
therapies. For clinical studies of cardiac resynchronization thera-
pies (CRT), quality of life (QoL)measures and exercise tolerance (ET)
measures have emerged as clinically relevant primary endpoints.
One objective measure of ET that has been used in several studies is
peak oxygen consumption (VO2). However, there is currently no
objectively justiﬁable precedence for how to select a universal
signal value to deﬁne “responder” or “success” for the peak VO2
measure used in clinical trials. In this section, we use data from two
published CRT studies to illustrate how the MinP responder anal-
ysis method can be applied to such studies.
The Multicenter InSync Randomized Clinical Evaluation (MIR-
ACLE) trial was a double-blind study of cardiac resynchronization in
patients with moderate-to-severe heart failure and a prolonged
QRS interval [8]. Approximately 400 patients were randomized and
implanted with a CRT device which was turned on in half of the
patients and left off in the other half for 6 months. A traditional
analysis evaluating between-group differences in mean changes of
the ET measurements was performed. The mean (±SD) change in
peak VO2 between baseline and 6 months was 0.2 ± 3.8 mL/kg/min
in the control group and 1.1 ± 3.5 mL/kg/min in the treatment
group. Signiﬁcant treatment effect was established based on this
analysis of peak VO2 in continuous scale. Assuming that the data are
normally distributed, these numbers can be used to construct
estimated distributions of the data.
We intend to determine whether a clinically signiﬁcant
Table 1
Type I error and power for detecting treatment difference (A) in means; (B) in responder rates with a pre-speciﬁed responder cutoff (10, 20, 30, …, 90); and (C) with MinP
procedure. The sample size per group is 200.
Conﬁguration (A) difference in means (B) difference in responder rates with pre-speciﬁed cutoff values: (C) MinP
10 20 30 40 50 60 70 80 90
(1) m ¼ 0 0.050 0.038 0.039 0.040 0.038 0.039 0.036 0.043 0.040 0.037 0.049
(2) m ¼ 2 0.483 0.324 0.325 0.333 0.324 0.333 0.320 0.311 0.324 0.326 0.363
(3) m ¼ 3 0.826 0.622 0.622 0.632 0.647 0.635 0.632 0.639 0.642 0.640 0.704
(4) m ¼ 4 0.964 0.834 0.831 0.827 0.830 0.831 0.825 0.824 0.823 0.834 0.877
Results are based on 5000 simulations and 2000 permutations.
Table 2
Type I error and power for detecting treatment difference (A) in means; (B) in responder rates with a pre-speciﬁed responder cutoff (0.1, 0.2, 0.3,…, 0.9); and (C) with MinP
procedure. The sample size per group is 200.
Conﬁguration (A) difference in means (B) difference in responder rates with pre-speciﬁed cutoff values: (C) MinP
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
(1) bA ¼ 2.0, bB ¼ 2.0 0.050 0.025 0.036 0.038 0.042 0.036 0.036 0.039 0.038 0.024 0.046
(2) bA ¼ 2.2, bB ¼ 2.0 0.274 0.050 0.092 0.120 0.161 0.182 0.210 0.198 0.154 0.072 0.225
(3) bA ¼ 2.4, bB ¼ 2.0 0.673 0.096 0.202 0.325 0.410 0.504 0.531 0.509 0.418 0.182 0.607
(4) bA ¼ 2.6, bB ¼ 2.0 0.917 0.127 0.334 0.534 0.661 0.763 0.789 0.762 0.670 0.258 0.867
Results are based on 5000 simulations and 2000 permutations.
Table 3
Power for detecting treatment difference (A) in means; (B) in responder rates with a pre-speciﬁed responder cutoff (0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 mL/kg/min); and (C) with the
MinP procedure. The sample size per group is 200 for both the MIRACLE trial and the COMPANION trial.
Scenario (A) difference in means (B) difference in responder rates with pre-speciﬁed cutoff values (mL/kg/min): (C) MinP
0.5 0.6 0.7 0.8 0.9 1.0
(1) MIRACLE trial 0.743 0.582 0.594 0.592 0.582 0.588 0.572 0.631
(2) COMPANION trial 0.667 0.399 0.427 0.435 0.443 0.445 0.460 0.510
Results are based on 5000 simulations and 2000 permutations.
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responder rates had a responder analysis, either the traditional
responder analysis with a single pre-speciﬁed cutoff point or the
MinPmethod, been planned as the primary analysis. A total of 5000
simulated trials were conducted. Seven (7) plausible cutoffs for
peak VO2 measure are used to deﬁned response: at least 0.5, 0.6,
0.7, 0.8, 0.9, and 1.0 mL/kg/min increase from baseline 6 months.
Three analysis strategies are compared: 1) comparison of the
means of the two groups; 2) responder analysis, i.e. comparison of
responder rates with the pre-speciﬁed responder cutoff; and 3) the
MinP procedure for responder analysis. The power of each test to
detect signiﬁcant differences is reported in Table 3. As can be seen,
the continuous test still provides the greatest power (74.3%), but
MinP is able to improve power by 4%e6% for responder analysis.
This evaluation can be repeated with data from the Comparison
of Medical, Pacing, and Deﬁbrillation Therapies in Heart Failure
(COMPANION) clinical trial, where subjects were randomized in a
1:4 ratio to optimal medical therapy (OPT) or to OPT plus CRT [9]. In
the COMPANION Sub-study, cardiopulmonary exercise testing (peak
VO2) was assessed as the primary endpoint, and success was deﬁned
as occurring if peak VO2 improved  0.7 mL/kg/min at 6 months of
assigned therapy. The mean (±SD) change in peak VO2 between
baseline and 6 months was 0.6 ± 2.7 mL/kg/min in the control OPT
group and 1.2 ± 3.0 mL/kg/min in the CRT group. The primary
endpoint was not met in this study. We are interested to see if the
study power could have been improved if a MinP responder analysis
approachwas used. Similarly using simulated data from the trial, we
report in Table 3 the power of each analysis strategy to detect sig-
niﬁcant differences. In this case, theMinPmethod is able to improve
the power of responder analysis by 5%e11%.5. Discussion and conclusions
A responder analysis is one in which each subject is classiﬁed as
either a “responder” or a “non-responder”, and the proportions of
patients who beneﬁt are quantiﬁed and compared between treat-
ment groups. The use of responder analysis is often recommended
by regulatory guidance, especially in trials where “soft” clinical
endpoints such as rating scales are used to evaluate treatments.
Although the responder analysis is in common use, it has sub-
stantial disadvantages. It has been widely acknowledged that the
main concern about the responder analysis is the arbitrary nature
of the deﬁnition of a response. A second problem with the analysis
is the dramatic reduction in statistical power by dichotomizing
continuous endpoints. In this paper, we address these two issues
together by proposing a novel approach for responder analysis that
could both improve the power of responder analysis and explore
different responder cutoffs if an agreed-upon common cutoff is not
present. Speciﬁcally, we propose a statistically rigorous clinical trial
design that pre-speciﬁes multiple tests of responder rates between
treatment groups based on a range of pre-speciﬁed responder
cutoffs, and uses the minimum of the p-values for formal inference.
The MinP procedure enables us to both establish the treatment
effect and ﬁnd the responder cutoff at the same time. Hence we
recommend prospectively incorporating the multiple testing and
permutation procedures into the study design and describe them in
the study protocol. his method can be most useful in Phase II
studies where such exploration and selection of responder cutoff
points are appropriate. The information learned and the optimal
cutoff selected from this study can then be carried forward to
future, Phase III trials which perhaps are less likely to implement
such ﬂexible design.
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required for a study designed using the proposed MinP method.
The clinical trialists should be considerate in the selection of
candidate cutoff points; only cutoff values that represent a clinically
meaningful treatment effect should be included in the design and
analysis plan. Statistical judgment should also be in place to include
a reasonable number of candidate cutoff values to avoid adversely
affecting the sample size required.
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